|
Oct 9
|
Knight Therapeutics Inc (KHTRF) Q2 2024 Earnings Call Highlights: Record Revenues and Strategic ...
|
|
May 12
|
Knight Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 9
|
Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1
|
|
May 9
|
Knight Therapeutics Reports First Quarter 2024 Results
|
|
May 9
|
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
|
|
May 8
|
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
|
|
May 7
|
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City
|
|
Mar 28
|
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
|
|
Mar 24
|
Knight Therapeutics Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
|
|
Dec 19
|
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
|
|
Nov 9
|
Knight Therapeutics Reports Third Quarter 2023 Results
|
|
Aug 10
|
Knight Therapeutics Reports Second Quarter 2023 Results
|